^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

VHL mutation

i
Other names: VHL, von Hippel-Lindau tumor suppressor, RCA1, VHL1, pVHL, HRCA1
Entrez ID:
Related biomarkers:
9d
Familial Von Hippel-Lindau Disease: A Case Series of Cerebral Hemangioblastomas with MRI, Histopathological, and Genetic Correlations. (PubMed, Life (Basel))
Genetic analysis showed patients one and two presented mutations in the VHL gene, confirming the VHL diagnosis. While the cases presented here follow the general lines for VHL disease, patients are related to each other, present tumors of the nervous system and mutations in the VHL gene, their particularities of presentation and manifestation bring new insights into this rare genetic disease.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
11d
Recurrent mTOR pathway alterations in renal cell carcinoma with hemangioblastoma-like features: A multi-institutional study of 9 cases with expanding morphologic spectrum. (PubMed, Virchows Arch)
Over a median follow-up of 50 months (range, 4-114 months), all patients remained disease-free. Our study confirms that RCC with HB-like features represents a distinct morphological pattern within the HB to RCC with fibromyomatous stroma continuum and establishes its expanded morphological spectrum and indolent biological behavior.
Clinical • Journal
|
TSC2 (TSC complex subunit 2) • CA9 (Carbonic anhydrase 9) • VIM (Vimentin) • MME (Membrane Metalloendopeptidase) • GPNMB (Glycoprotein Nmb) • PAX8 (Paired box 8)
|
VHL mutation
14d
The truth behind multiple neuroendocrine tumors: Von Hippel-Lindau syndrome and its diagnostic challenges-A case report and literature review. (PubMed, Sci Prog)
Analyzing this case alongside the literature highlights the need to suspect VHL in young patients with multiple tumors, for whom genetic testing is crucial for definitive diagnosis. While a single case cannot capture the full disease spectrum, it provides valuable clinical insight.
Review • Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
20d
Primary hemangioblastoma of rectum: a rare case report and review of literature. (PubMed, J Cancer Res Clin Oncol)
This case underscored the importance of considering hemangioblastoma in the differential diagnosis of rectal submucosal lesions. It highlighted the need for a thorough diagnostic approach that integrates colonoscopic evaluation with histopathological examination, particularly in patients presenting with altered stool consistency or melena. Furthermore, the NGS results implicated that TSC, SDH and PTEN may contribute to hemangioblastoma development. These alterations could constitute a novel diagnostic signature, a premise that warrants definitive investigation through larger, multi-institutional studies.
Review • Journal
|
PTEN (Phosphatase and tensin homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
23d
Manipulation with Mutational Status of VHL Regulates Hypoxic Metabolism and Pro-Angiogenic Phenotypes in ccRCC Caki-1 Cells. (PubMed, Int J Mol Sci)
Using single cell transcriptomics, we show that the VHL-positive and -negative Caki-1 cells are characterized with different proportions of benign and aggressive cells as seen by analysis of specific gene expression. Furthermore, the identified angiogenesis-related genes were linked to affect clinical outcomes in ccRCC patients, suggesting that VHL restoration may mitigate high-risk molecular features.
Journal
|
VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1)
|
VHL mutation
23d
Types of pancreatic lesions and the mutational landscape of the VHL gene in patients with von Hippel-Lindau disease. (PubMed, Pancreatology)
Pancreatic lesions are common in VHL disease. Mutations in codons 161 and 167 are hotspots in patients with pancreatic lesions, particularly NETs.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
1m
Case Report: von Hippel-Lindau (VHL) disease: a young female presenting with multiple organ tumors. (PubMed, Front Genet)
This case underscores the importance of considering hereditary genetic syndromes in patients presenting with hypertension and multi-system tumor involvement. Comprehensive evaluation, standardized familial screening, and genetic testing play a crucial role in guiding treatment decisions for affected individuals.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
1m
A Rare Case of Metastatic Carotid Body Paraganglioma: A 7-Year Asymptomatic Period. (PubMed, Case Rep Oncol Med)
This case highlights an unusual clinical course: a carotid body paraganglioma, initially asymptomatic and successfully resected, developed skeletal metastasis after a prolonged disease-free interval of 7 years. This report underscores the importance of revisiting conventional risk stratification, incorporating genetic testing, and ensuring vigilant, long-term follow-up.
Journal
|
NF1 (Neurofibromin 1) • VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
|
RET mutation • VHL mutation
1m
Multisystemic Presentation of Von Hippel-Lindau Disease Revealed by Pheochromocytoma and Takotsubo Syndrome. (PubMed, JACC Case Rep)
Takotsubo syndrome may be the initial manifestation of VHL-associated pheochromocytoma. Systematic genetic evaluation and family screening are crucial in hereditary tumor syndromes.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
1m
JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management. (PubMed, Am J Hematol)
Advances in molecular hematology are expected to improve the characterization of "idiopathic erythrocytosis". Results from prospective studies are needed to elucidate the underlying pathology and guide management.
Review • Journal
|
JAK2 (Janus kinase 2) • EPAS1 (Endothelial PAS domain protein 1) • EPOR (Erythropoietin Receptor) • EPO (Erythropoietin)
|
VHL mutation
|
aspirin
2ms
D-mannose suppresses HIF-1α mediated metabolic reprogramming in clear cell renal cell carcinoma. (PubMed, Discov Oncol)
Furthermore, D-mannose reduces glucose uptake and intracellular lactate and NADPH production. To sum up, this study demonstrates that targeting HIF-1α by D-mannose to inhibit metabolic reprogramming is a promising strategy for ccRCC and complements a previously unknown role of D-mannose in cancer treatment.
Journal
|
LDHA (Lactate dehydrogenase A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
VHL mutation
2ms
HIFα isoform specific activities drive cell-type specificity of VHL-associated oncogenesis. (PubMed, Nat Commun)
Here, we reveal markedly different consequences of HIF1A and HIF2A activation, but that both contribute to renal cell-type specific consequences of VHL-inactivation in the kidney. Early involvement of HIF2A in promoting proliferation within the proximal tubular epithelium supports therapeutic targeting of HIF2A early in VHL disease.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1)
|
VHL mutation